Health Headlines: Breakthroughs and Controversies in Focus

The FDA approved a new Lantheus prostate cancer imaging agent. South Carolina's measles cases rise. Medtronic's MiniMed shares drop in Nasdaq debut. A French probe exonerates Nestle in a baby death case. Servier acquires Day One Biopharma. Novo and Hims end their feud. Tylenol use declines after Trump's autism remarks.

The FDA has approved a new formulation of Lantheus Holdings' prostate cancer imaging agent to enhance scanning access, triggering a 4% increase in the company's shares. South Carolina reports an increase in measles cases to 991, with a significant rise in vaccination rates noted.

Medtronic's MiniMed diabetes business faced a challenging debut on Nasdaq, opening 4.8% below the offer price amid market volatility attributed to AI disruption and geopolitical tensions. French investigators found no link between the Nestle infant formula and a baby's death, though recalls have been triggered over toxin concerns.

In corporate developments, Servier moves to acquire Day One Biopharma for $2.5 billion, boosting its brain tumor treatment division. Novo Nordisk and Hims have resolved their legal dispute over weight-loss drugs, and Tylenol use among pregnant women declines following Trump's controversial statements tying it to autism.